… of TGF-β inhibitors in breast cancer. Specific TGF-β pharmacological inhibitors suppress
canonical and non-canonical TGF-β signaling by inhibiting TGF-β receptors phosphorylation, …

… To better understand the potential risk of inducing autoimmunity after administration of
TGF-β inhibitors, clinical experiences with pharmacological agents blocking regulatory T cells …

… Because TGF-β is a potent stimulus for extracellular matrix synthesis, inhibition of ALK5 …
Therefore, we examined kinase inhibitors for their ability to inhibit the TGF-β type I receptor …

… In conclusion, pharmacologic inhibition of TGF-β signaling in postnatal bone increases bone
quality. Coupling of osteoblast and osteoclast activity may be critical for the ability of TGF-β …

… reported that transforming growth factor β (TGF-β) is … the therapeutic action of an inhibitor of
TGF-β signaling (SB-431542) … In conclusion, inhibition of TGF-β signaling in vivo appears to …

… We have proposed that pharmacological inhibition of TGF R can be considered a new … The
concept of a pharmacological inhibition of TGF-1 is different from that of a multikinase inhibitor…

… , inhibited TGF-β–induced EMT (the “pro-EMT” group) and the second group of kinases whose
inhibition … to cancer and the availability of pharmacologic inhibitors, we sought to further …

… We also summarize the clinical impact of TGF-β inhibitors in HCC patients and provide a
perspective on its future use alone or in combinatorial strategies for HCC treatment. …

… and myostatin is a known inhibitor of satellite cell … TGF-β receptor signaling (including
elevated pSmad3 and p15), and the rescue of muscle repair in vivo by pharmacological inhibitors …

… We review here the rationale for targeting TGF-β signaling in cancer and summarize the
clinical status of pharmacological inhibitors. We discuss the direct effects of TGF-β signaling …